针对H. pylori抗原的M细胞SAM-FAdE显示在类似细菌的颗粒上,诱导保护性免疫力
Furui Zhang1,2,3, Jiale Chen1, Zhen Zhang4
1School of First Clinical Medical, Ningxia Medical University, Yinchuan, 750004, China.
Journal of nanobiotechnology
|January 17, 2025
概括
开发了一种新型口服疫苗,使用具有H. pylori抗原的细菌样颗粒 (BLPs) 有效地向M细胞,诱导强大的免疫反应,并显著减少H. pylori感染和胃损伤.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 疫苗开发 疫苗开发
背景情况:
- 杆菌 (H. pylori) 是胃癌的主要原因之一.
- 开发针对H. pylori的粘膜疫苗对于治疗胃炎和预防胃癌至关重要.
研究的目的:
- 使用类似细菌的颗粒 (BLPs) 开发一种有效的粘膜疫苗来对抗H. pylori.
- 评估疫苗向M细胞并诱导免疫反应的能力.
- 评估疫苗在减少H. pylori感染和胃损伤方面的有效性.
主要方法:
- 通过用热酸处理乳酸细菌 (L. lactis) 来产生类似细菌的颗粒 (BLPs).
- 在BLP上显示了一种H. pylori多表位抗原 (SAM-FAdE),效率高 (90%).
- BLPs-SAM-FAdE疫苗被口服给小鼠,以评估M细胞向,免疫细胞成熟和免疫反应诱导.
主要成果:
- BLPs-SAM-FAdE有效地准了M细胞模型和小鼠皮耶尔贴片,促进了疫苗输送到树突细胞并刺激了它们的成熟.
- 观察到血细胞和生殖中心B细胞的显著增加.
- 该疫苗诱导了抗原特异性粘膜 (sIgA),T细胞 (CD4+,Th1/Th2/Th17) 和幽默性 (血清IgG) 免疫反应.
- 口服BLPs-SAM-FAdE显著降低了胃组织中的H. pylori粘附和16SrRNA表达,防止损伤.
结论:
- BLPs-SAM-FAdE显示出作为一种口服针对H. pylori的疫苗的显著潜力.
- 该疫苗有效地减少了H. pylori的粘附,并抑制了胃炎和胃损伤.
相关概念视频
Defense Against Bacterial Pathogens
1.4K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.4K
Antigens Involved in Adaptive Immunity
448
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
448
Cell-mediated Immune Responses
66.8K
Overview
66.8K
B Cell Activation and Differentiation
1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K
Humoral Immune Responses
71.3K
Overview
71.3K
Immune Response Against Viral Pathogens
738
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
738


